• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by PRESIDENT Ryan Charles S.

    2/11/25 5:43:17 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $QNCX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Ryan Charles S.

    (Last) (First) (Middle)
    C/O QUINCE THERAPEUTICS, INC.
    611 GATEWAY BLVD, SUITE 273

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Quince Therapeutics, Inc. [ QNCX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    PRESIDENT
    3. Date of Earliest Transaction (Month/Day/Year)
    01/28/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (right to buy) $1.6 01/28/2025 A 300,000 (1) 01/27/2035 Common Stock 300,000 $0 300,000 D
    Explanation of Responses:
    1. The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2025, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.
    /s/ Brendan Hannah, Attorney-in-Fact 02/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $QNCX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QNCX

    DatePrice TargetRatingAnalyst
    3/24/2025$10.00Outperform
    Oppenheimer
    More analyst ratings

    $QNCX
    SEC Filings

    See more
    • SEC Form 8-K filed by Quince Therapeutics Inc.

      8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

      6/5/25 4:12:42 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Quince Therapeutics Inc.

      10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

      5/13/25 8:40:57 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

      5/13/25 8:01:26 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) has reached an important milestone as enrollment now exceeds 75% with a total of 65 participants randomized in the study's targeted 86 participants in the six to nine year-old primary analysis population. Key Phase 3 NEAT clinical trial enrollment highlights to date include: A total of 76 participants have been enr

      6/3/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

      Plan to potentially conclude enrollment early for Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T) to align topline results with existing cash runway Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the first quarter ended March 31, 2025. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "In light of current cash runway and with the goal of maximizing a capital efficient development plan, Quince has made the strategic business de

      5/13/25 8:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics to Present at Citizens Life Sciences Conference

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time. A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event. About Quince Therapeutics

      4/30/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Financials

    Live finance-specific insights

    See more
    • Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.

      4/5/23 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ryan Una S

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/6/25 5:52:41 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Benatti Luca

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/6/25 5:38:57 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Senner Christopher J.

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      6/6/25 5:36:21 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $QNCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $QNCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $QNCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $QNCX
    Leadership Updates

    Live Leadership Updates

    See more
    • Oppenheimer initiated coverage on Quince Therapeutics with a new price target

      Oppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $10.00

      3/24/25 8:40:42 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      9/3/24 5:38:44 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      8/22/24 5:51:16 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

      4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

      8/21/24 6:38:07 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

      SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

      11/14/24 4:00:05 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Quince Therapeutics Inc.

      SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)

      11/13/24 9:17:26 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

      SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

      8/6/24 8:04:44 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn

      1/23/25 4:05:00 PM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company's Board of Directors. "We are pleased to welcome a proven clinical development leader of Dr. Rajiv Patni's caliber to our Board of Directors," said David Lamond, chairperson of Quince's Board of Directors. "With expertise that spans the continuum from translational to registrational studies and regulatory agency negotiation in several rare diseases, we lo

      2/15/24 7:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Quince Therapeutics Appoints Dr. Charles S. Ryan as President

      Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company's corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince. Dirk Thye, M.D., Quince's Chief Executive Officer, said, "Charles is a valuable addition to our management team. His considera

      9/6/23 7:00:00 AM ET
      $QNCX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care